EWPI Emerging World Pharma Inc (CE)

Emerging World Pharma Inc. (PINKSHEETS: EWPI) -- Emerging World Pharma's strategic partner, AFRICAN GLOBAL PHARMA is pleased to announce that the GHANA FDB has given approval for the registration of its "GLATEN TABLETS" ATENOLOL 50MG pursuant to section 18 of the Food and Drugs Act of 1992(PNDCL 305B).

Atenolol is a drug from the group of beta blockers. Beta blockers or ß-blockers are a group or class of drugs used mostly in cardiovascular or heart diseases.

African Global Pharma will begin the manufacturing of ATENOLOL 50MG branded Glaten tablets immediately. This represents the Company's debut in the generic pharmaceutical market in Ghana and it looks forward to more approvals this quarter as it continues its submissions with the FDB.

For more information please visit our website at www.globalpharmacorp.com

About Global-Pharma Corporation

Since 1996 Global Pharma has been producing top quality USP generics at competitive prices based on a low overhead corporate model. We choose to provide advanced pharmaceutical solutions to our customers which directly translates to cost savings when compared to our competitors. Global Pharma ensures the highest quality of all production products by augmenting each manufacturing facility with a 'Quality Assurance' team. These teams of highly trained technicians ensure that 'GMP' (Good Manufacturing Compliance) and 'WHO' (World Health Organization) compliance is matched or exceeded.

www.emrgingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com